Neupulse
Nottingham
About Neupulse
Neupulse is the brand of Neurotherapeutics Ltd The direction of our current research was very much shaped by the feedback we received from individuals with tic disorders and their families. When we asked them for their thoughts on our research priorities we were frequently told that what was really needed was a safe and effective non-drug treatment for tic disorder that could be used outside of the clinic and gave individuals control over their tics. This led directly to us focusing on the use of peripheral nerve stimulation as a means of bringing about changes in the brain networks associated with the production of tics. We demonstrated that delivering rhythmic patterns of mild electrical stimulation to the median nerve at the wrist could be used to increase the power and the synchronicity of the brain oscillations (rhythms) associated with the suppression of movements, and that this type of stimulation was sufficient to dramatically reduce the frequency of tics and remove the urge-to-tic in individuals with tic disorders. Importantly, we also showed that this type of stimulation did not materially affect the execution of volitional (intentional) movements or impair cognitive functions such as attention.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $7.9M
- Funding stage: Seed
- Last round: Seed (Feb 2026)
- Website: neupulse.co.uk
Industries & Categories
Health Care, Hospital
Social Profiles
Canonical: https://fsome.com/organization/neupulse-114413 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.